Preserving Duodenal-Jejunal (Foregut) Transit Does Not Impair Glucose Tolerance and Diabetes Remission Following Gastric Bypass in Type 2 Diabetes Sprague-Dawley Rat Model
- 2 November 2017
- journal article
- research article
- Published by Springer Nature in Obesity Surgery
- Vol. 28 (5) , 1313-1320
Abstract
Background Possible mechanisms underlying diabetes remission following Roux-en-Y gastric bypass (RYGB) include eradication of putative factor(s) with duodenal-jejunal bypass. Objective The objective of this study is to observe the effects of duodenal-jejunal transit on glucose tolerance and diabetes remission in gastric bypass rat model. Method In order to verify the effect of duodenal-jejunal transit on glucose tolerance and diabetes remission in gastric bypass, 22 type 2 diabetes Sprague-Dawley rat models established through high-fat diet and low-dose streptozotocin (STZ) administered intraperitoneally were assigned to one of three groups: gastric bypass with duodenal-jejunal transit (GB-DJT n = 8), gastric bypass without duodenal-jejunal transit (RYGB n = 8), and sham (n = 6). Body weight, food intake, blood glucose, as well as meal-stimulated insulin, and incretin hormone responses were assessed to ascertain the effect of surgery in all groups. Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were conducted three and 7 weeks after surgery. Results Comparing our GB-DJT to the RYGB group, we saw no differences in the mean decline in body weight, food intake, and blood glucose 8 weeks after surgery. GB-DJT group exhibited immediate and sustained glucose control throughout the study. Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) levels were also significantly increased from preoperative level in the GB-DJT group (p < 0.05). Insulin and GLP-1 area under curve (AUC) as well as improved glycemic excursion on OGTT did not differ between GB-DJT and RYGB groups. Outcomes with sham operation did not differ from preoperative level. Conclusion Preserving duodenal-jejunal transit does not impede glucose tolerance and diabetes remission after gastric bypass in type-2 diabetes Sprague-Dawley rat model.Keywords
Funding Information
- Natural Science Foundation of Jiangsu Province (2015102015)
This publication has 29 references indexed in Scilit:
- Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose toleranceAmerican Journal of Physiology-Endocrinology and Metabolism, 2012
- Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgeryAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2011
- Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 SecretionDiabetes Care, 2009
- Role of the incretin system in the remission of type 2 diabetes following bariatric surgeryNutrition, Metabolism and Cardiovascular Diseases, 2008
- Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2008
- The Characterization of High‐Fat Diet and Multiple Low‐Dose Streptozotocin Induced Type 2 Diabetes Rat ModelJournal of Diabetes Research, 2008
- Reduced Incretin Effect in Type 2 DiabetesDiabetes, 2007
- How the hindgut can cure type 2 diabetes. Ileal transposition improves glucose metabolism and beta-cell function in Goto-kakizaki rats through an enhanced Proglucagon gene expression and L-cell numberSurgery, 2007
- The Early Effect of the Roux-en-Y Gastric Bypass on Hormones Involved in Body Weight Regulation and Glucose MetabolismAnnals of Surgery, 2004
- A surgical rat model of human roux-en-Y gastric bypassJournal of Gastrointestinal Surgery, 2004